SoftOx Solutions AS ( (DE:6FV) ) has shared an update.
SoftOx Solutions AS has undergone significant restructuring to focus on segmented business areas, including the spin-out of its Wound & Skin Care division into a separate entity. This strategic realignment allows the company to concentrate on inhalation-therapeutics, particularly for Ventilator-Associated Pneumonia, and continue its defense initiatives. The company is also addressing financial challenges through a private placement of shares to secure funding for upcoming clinical trials.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company based in Oslo, Norway, and listed on Euronext Growth Oslo. The company specializes in developing pan-antimicrobial technology targeting bacteria, viruses, and fungi, with operations extending to subsidiaries in Sweden and Denmark. Their focus includes inhalation-therapeutics and medical countermeasures against biological warfare agents.
Technical Sentiment Signal: Buy
Current Market Cap: €8.15M
Find detailed analytics on 6FV stock on TipRanks’ Stock Analysis page.